Bin Gao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2636375/publications.pdf

Version: 2024-02-01

239 papers	26,772 citations	4146 87 h-index	6996 154 g-index
244 all docs	244 docs citations	244 times ranked	26592 citing authors

#	Article	IF	Citations
1	E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8/9. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 151-171.	4.5	26
2	Aging exaggerates acuteâ€onâ€chronic alcoholâ€induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1â€C/EBPÎ±â€miRNAâ€223 axis. Hepatology, 2022, 75, 646-660.	7.3	29
3	Interplay of Gut Microbes and Aryl Hydrocarbon Receptor in Alcohol-Associated Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 343-345.	4.5	0
4	Inflammation in alcohol-associated liver disease progression. Zeitschrift Fur Gastroenterologie, 2022, 60, 58-66.	0.5	2
5	Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. Journal of Clinical Investigation, 2022, 132, .	8.2	23
6	Myeloidâ€Cellâ€“Specific ILâ€6 Signaling Promotes MicroRNAâ€223â€Enriched Exosome Production to Attenuate NAFLDâ€Associated Fibrosis. Hepatology, 2021, 74, 116-132.	7.3	99
7	Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cellular and Molecular Immunology, 2021, 18, 18-37.	10.5	70
8	MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 2021, 70, 784-795.	12.1	260
9	MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types. International Journal of Biological Sciences, 2021, 17, 1153-1167.	6.4	17
10	Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223â€“enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. Journal of Clinical Investigation, 2021, 131, .	8.2	85
11	Brain ethanol metabolism by astrocytic ALDH2 drives the behavioural effects of ethanol intoxication. Nature Metabolism, 2021, 3, 337-351.	11.9	61
12	Bile acidâ€“activated macrophages promote biliary epithelial cell proliferation through integrin Î±vÎ²6 upregulation following liver injury. Journal of Clinical Investigation, 2021, 131, .	8.2	46
13	Kupffer cell restoration after partial hepatectomy is mainly driven by local cell proliferation in IL-6-dependent autocrine and paracrine manners. Cellular and Molecular Immunology, 2021, 18, 2165-2176.	10.5	22
14	Acute-on-chronic liver failure: A distinct clinical syndrome. Journal of Hepatology, 2021, 75, S27-S35.	3.7	55
15	Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IÎºBÎ¶ target genes in hepatocytes. Journal of Hepatology, 2021, 75, 163-176.	3.7	12
16	Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia. Molecules, 2021, 26, 5089.	3.8	4
17	From basic liver immunology to therapeutic opportunities for liver diseases. Cellular and Molecular Immunology, 2021, 18, 1-3.	10.5	13
18	Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. Frontiers in Endocrinology, 2021, 12, 751802.	3.5	32

#	Article	IF	Citations
19	Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player. Journal of Clinical Investigation, 2021, 131, .	8.2	13
20	Î³ÎT Cells and CD1d, Novel Immune Players in Alcoholic and Nonalcoholic Steatohepatitis?. Hepatology, 2020, 71, 408-410.	7.3	6
21	Interleukinâ€22 Ameliorates Neutrophilâ€Driven Nonalcoholic Steatohepatitis Through Multiple Targets. Hepatology, 2020, 72, 412-429.	7.3	100
22	IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. Journal of Hepatology, 2020, 72, 946-959.	3.7	113
23	Hepatic injury and inflammation alter ethanol metabolism and drinking behavior. Food and Chemical Toxicology, 2020, 136, 111070.	3.6	11
24	Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. Journal of Hepatology, 2020, 72, 736-745.	3.7	109
25	An Openâ€Label, Doseâ€Escalation Study to Assess the Safety and Efficacy of ILâ€22 Agonist Fâ€652 in Patients With Alcoholâ€associated Hepatitis. Hepatology, 2020, 72, 441-453.	7.3	107
26	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	12.1	112
27	Reply to: â€œInterleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?â€• Journal of Hepatology, 2020, 73, 982-984.	3.7	1
28	Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. Scientific Reports, 2020, 10, 15558.	3.3	30
29	Interleukin-22 in alcoholic hepatitis and beyond. Hepatology International, 2020, 14, 667-676.	4.2	18
30	Distinct fate, dynamics and niches of renal macrophages of bone marrow or embryonic origins. Nature Communications, 2020, 11, 2280.	12.8	62
31	Disulfiram Treatment Normalizes Body Weight in Obese Mice. Cell Metabolism, 2020, 32, 203-214.e4.	16.2	46
32	Protective and Detrimental Roles of p38Î± Mitogenâ€Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 72, 873-891.	7.3	42
33	Beyond Metabolism: Role of the Immune System in Hepatic Toxicity. International Journal of Toxicology, 2020, 39, 151-164.	1.2	11
34	Interleukin-22 acts as a mitochondrial protector. Theranostics, 2020, 10, 7836-7840.	10.0	5
35	Reply to Brewer: Liver-targeted ALDH2 inhibition may reduce alcohol-seeking behaviors with limited side effects. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7573-7574.	7.1	0
36	Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice. JCI Insight, 2020, 5, .	5.0	29

#	Article	IF	Citations
37	Chronic-plus-binge alcohol intake induces production of proinflammatory mtDNA-enriched extracellular vesicles and steatohepatitis via ASK1/p38MAPKÎ±-dependent mechanisms. JCI Insight, 2020, 5, .	5.0	34
38	Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake. Clinical and Molecular Hepatology, 2020, 26, 586-594.	8.9	20
39	Immunopathogenesis of Liver Cirrhosis. , 2020, , 583-595.		1
40	Pregnane X Receptor Regulates Liver Size and Liver Cell Fate by Yesâ€Associated Protein Activation in Mice. Hepatology, 2019, 69, 343-358.	7.3	66
41	Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cellular and Molecular Immunology, 2019, 16, 666-667.	10.5	45
42	Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids. Gut, 2019, 68, 1311-1322.	12.1	44
43	Versatile cell ablation tools and their applications to study loss of cell functions. Cellular and Molecular Life Sciences, 2019, 76, 4725-4743.	5.4	16
44	ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. Journal of Hepatology, 2019, 71, 1000-1011.	3.7	117
45	Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. Cell Metabolism, 2019, 30, 877-889.e7.	16.2	68
46	Adipocyte Death Preferentially Induces Liver Injury and Inflammation Through the Activation of Chemokine (Câ€C Motif) Receptor 2â€Positive Macrophages and Lipolysis. Hepatology, 2019, 69, 1965-1982.	7.3	47
47	Hippo signaling is intrinsically regulated during cell cycle progression by APC/C ^{Cdh1}. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9423-9432.	7.1	48
48	Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miRâ€23aâ€3p and Upâ€regulate Programmed Death Ligand 1 Expression in Macrophages. Hepatology, 2019, 70, 241-258.	7.3	304
49	Global liver disease burdens and research trends: Analysis from a Chinese perspective. Journal of Hepatology, 2019, 71, 212-221.	3.7	327
50	MicroRNAâ€223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes. Hepatology, 2019, 70, 1150-1167.	7.3	104
51	Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25974-25981.	7.1	41
52	Summary of the 2018 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol, 2019, 77, 11-18.	1.7	4
53	Inflammatory pathways in alcoholic steatohepatitis. Journal of Hepatology, 2019, 70, 249-259.	3.7	238
54	How does your fat affect your liver when you drink?. Journal of Clinical Investigation, 2019, 129, 2181-2183.	8.2	6

#	Article	IF	Citations
55	DEP domainâ€“containing mTORâ€“interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acuteâ€onâ€chronic liver injury in alcoholic liver disease. Hepatology, 2018, 68, 496-514.	7.3	85
56	Interleukinsâ€17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. Hepatology Communications, 2018, 2, 329-343.	4.3	19
57	Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalinâ€2 and neutrophil extracellular traps. Hepatology, 2018, 68, 1604-1620.	7.3	47
58	Neutrophilâ€“Hepatic Stellate Cell Interactions Promote Fibrosis inÂExperimental Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 399-413.	4.5	95
59	Î²â€Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice. British Journal of Pharmacology, 2018, 175, 320-334.	5.4	68
60	IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-ÎºB activation in hepatic macrophages. Journal of Hepatology, 2018, 68, 109-117.	3.7	22
61	Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. Gut, 2018, 67, 1692-1703.	12.1	122
62	Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 50-59.	17.8	134
63	MAIT cells: a novel therapeutic target for alcoholic liver disease?. Gut, 2018, 67, 784-786.	12.1	16
64	Epidemiology and Pathogenesis of Alcoholic Liver Disease. , 2018, , 334-344.e3.		3
65	Ethanol and unsaturated dietary fat induce unique patterns of hepatic ï‰-6 and ï‰-3 PUFA oxylipins in a mouse model of alcoholic liver disease. PLoS ONE, 2018, 13, e0204119.	2.5	25
66	Alcoholic liver disease. Nature Reviews Disease Primers, 2018, 4, 16.	30.5	660
67	Inflammation is independent of steatosis in a murine model of steatohepatitis. Hepatology, 2017, 66, 108-123.	7.3	56
68	MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6â€“p47^{phox}â€“oxidative stress pathway in neutrophils. Gut, 2017, 66, 705-715.	12.1	173
69	A small specificâ€sized hyaluronic acid ameliorates alcoholic liver disease by targeting a small RNA: New hope for therapy?. Hepatology, 2017, 66, 321-323.	7.3	6
70	Targeting inflammation for the treatment of alcoholic liver disease. , 2017, 180, 77-89.		60
71	Hepatic mitochondrial DNA/Tollâ€like receptor 9/MicroRNAâ€223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology, 2017, 66, 220-234.	7.3	106
72	Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-Î²-dependent emperipolesis in HBV cirrhotic patients. Scientific Reports, 2017, 7, 44544.	3.3	53

#	Article	IF	Citations
73	Role of gp91phox in hepatic macrophage programming and alcoholic liver disease. Hepatology Communications, 2017, 1, 765-779.	4.3	12
74	Dietary Linoleic Acid and Its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Proinflammatory Response in Mice. American Journal of Pathology, 2017, 187, 2232-2245.	3.8	55
75	Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Scientific Reports, 2017, 7, 12064.	3.3	78
76	Impairment of Hematopoietic Precursor Cell Activation during the Granulopoietic Response to Bacteremia in Mice with Chronic-Plus-Binge Alcohol Administration. Infection and Immunity, 2017, 85, .	2.2	10
77	Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death. American Journal of Physiology - Cell Physiology, 2017, 313, C305-C313.	4.6	27
78	Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression. Journal of Hepatology, 2017, 66, 601-609.	3.7	123
79	PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. Journal of Hepatology, 2017, 66, 589-600.	3.7	116
80	Animal Models of Alcoholic Liver Disease: Pathogenesis and Clinical Relevance. Gene Expression, 2017, 17, 173-186.	1.2	86
81	Mitochondrial DNAâ€“enriched microparticles promote acute-on-chronic alcoholic neutrophilia and hepatotoxicity. JCI Insight, 2017, 2, .	5.0	76
82	Chronic expression of interferonâ€gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology, 2016, 64, 1189-1201.	7.3	93
83	Alcoholic hepatitis: Translational approaches to develop targeted therapies. Hepatology, 2016, 64, 1343-1355.	7.3	91
84	Basic liver immunology. Cellular and Molecular Immunology, 2016, 13, 265-266.	10.5	87
85	The Detrimental Role Played by Lipocalin-2 in Alcoholic Fatty Liver in Mice. American Journal of Pathology, 2016, 186, 2417-2428.	3.8	39
86	Alcohol and Fat Promote Steatohepatitis: A Critical Role for Fat-Specific Protein 27/Cidec. Journal of Investigative Medicine, 2016, 64, 1078-1081.	1.6	4
87	The Role of IL-17 Signaling in Regulation of the Liverâ€“Brain Axis and Intestinal Permeability in Alcoholic Liver Disease. Current Pathobiology Reports, 2016, 4, 27-35.	3.4	23
88	Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?. Gastroenterology, 2016, 150, 1704-1709.	1.3	239
89	Therapeutic Role of Interleukin 22 in Experimental Intra-abdominal Klebsiella pneumoniae Infection in Mice. Infection and Immunity, 2016, 84, 782-789.	2.2	35
90	Hepatocytes: a key cell type for innate immunity. Cellular and Molecular Immunology, 2016, 13, 301-315.	10.5	299

#	Article	IF	Citations
91	Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. Cellular and Molecular Immunology, 2016, 13, 206-216.	10.5	70
92	Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration. Journal of Clinical Investigation, 2016, 126, 2321-2333.	8.2	27
93	Liver Fibrosis in Alcoholic Liver Disease. Seminars in Liver Disease, 2015, 35, 146-156.	3.6	93
94	Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences. Cell and Bioscience, 2015, 5, 25.	4.8	26
95	Pharmacological chaperone therapies: Can aldehyde dehydrogenase activator make us healthier?. Journal of Hepatology, 2015, 62, 1228-1230.	3.7	15
96	Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis. Gastroenterology, 2015, 149, 4-9.	1.3	25
97	A novel multivalent 99m Tc-labeled EG2-C4bpÎ± antibody for targeting the epidermal growth factor receptor in tumor xenografts. Nuclear Medicine and Biology, 2015, 42, 547-554.	0.6	11
98	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans. Gastroenterology, 2015, 149, 1030-1041.e6.	1.3	114
99	Inhibition of type I natural killer T cells by retinoids or following sulfatideâ€mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Hepatology, 2015, 61, 1357-1369.	7.3	95
100	Shortâ€or longâ€term highâ€fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: An important role for CXCL1. Hepatology, 2015, 62, 1070-1085.	7.3	152
101	Interplay of interleukinâ€22 and its binding protein in controlling liver scarring. Hepatology, 2015, 61, 1121-1123.	7.3	3
102	Combination therapy: New hope for alcoholic hepatitis?. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S7-S11.	1.5	29
103	Dietary Saturated Lipids in Alcoholic Liver Disease: NewÂMicrobiota-Targeting Bullets?. Gastroenterology, 2015, 148, 16-19.	1.3	7
104	Liver is the major source of elevated serum lipocalinâ€2 levels after bacterial infection or partial hepatectomy: A critical role for ILâ€6/STAT3. Hepatology, 2015, 61, 692-702.	7.3	143
105	Chronic Ethanol Consumption Inhibits Glucokinase Transcriptional Activity by Atf3 and Triggers Metabolic Syndrome in Vivo. Journal of Biological Chemistry, 2014, 289, 27065-27079.	3.4	42
106	MicroRNAs control hepatocarcinogenesis by regulating hepatocyte nuclear factor 4Î±-inflammatory signal feedback loops. Hepatology, 2014, 60, 1466-1468.	7.3	4
107	The global burden of liver disease: The major impact of China. Hepatology, 2014, 60, 2099-2108.	7.3	986
108	Activation of invariant natural killer T cells impedes liver regeneration by way of both IFN-Î³- and IL-4-dependent mechanisms. Hepatology, 2014, 60, 1356-1366.	7.3	32

#	Article	IF	Citations
109	New Approaches for Studying Alcoholic Liver Disease. Current Pathobiology Reports, 2014, 2, 171-183.	3.4	9
110	STAT4 Knockout Mice Are More Susceptible to Concanavalin Aâ€“Induced T-Cell Hepatitis. American Journal of Pathology, 2014, 184, 1785-1794.	3.8	22
111	Hepatic SIRT1 Attenuates Hepatic Steatosis and Controls Energy Balance in Mice by Inducing Fibroblast Growth Factor 21. Gastroenterology, 2014, 146, 539-549.e7.	1.3	240
112	Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology, 2014, 59, 1331-1342.	7.3	150
113	New drug targets for alcoholic liver disease. Hepatology International, 2014, 8, 475-480.	4.2	13
114	Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology, 2014, 59, 1998-2009.	7.3	103
115	Animals Models of Gastrointestinal and Liver Diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges. American Journal of Physiology - Renal Physiology, 2014, 306, G819-G823.	3.4	108
116	IL-22 Ameliorates Renal Ischemia-Reperfusion Injury by Targeting Proximal Tubule Epithelium. Journal of the American Society of Nephrology: JASN, 2014, 25, 967-977.	6.1	78
117	Chronic alcohol ingestion modulates hepatic macrophage populations and functions in mice. Journal of Leukocyte Biology, 2014, 96, 657-665.	3.3	109
118	Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. Hepatology, 2014, 59, 1094-1106.	7.3	44
119	Acute and Chronic Effects of IL-22 on Acetaminophen-Induced Liver Injury. Journal of Immunology, 2014, 193, 2512-2518.	0.8	55
120	Chemokines and alcoholic hepatitis: are chemokines good therapeutic targets?. Gut, 2014, 63, 1683-1684.	12.1	23
121	Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology, 2014, 60, 146-157.	7.3	149
122	Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice. Hepatology, 2014, 60, 1044-1053.	7.3	69
123	The Immunopathogenesis of Cirrhosis. , 2014, , 413-424.		2
124	Hepatoprotective and antiâ€fibrotic functions of interleukinâ€22: Therapeutic potential for the treatment of alcoholic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 56-60.	2.8	82
125	Liver Immunology. , 2013, 3, 567-598.		148
126	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology, 2013, 58, 1742-1756.	7.3	87

#	Article	IF	Citations
127	Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nature Protocols, 2013, 8, 627-637.	12.0	782
128	Natural killer cells in liver disease. Hepatology, 2013, 57, 1654-1662.	7.3	237
129	Natural killer and natural killer T cells in liver fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1061-1069.	3.8	118
130	Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease. Hepatology, 2013, 57, 2078-2080.	7.3	26
131	Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: A critical role for E-selectin. Hepatology, 2013, 58, 1814-1823.	7.3	233
132	IFN-Î³ inhibits liver progenitor cell proliferation in HBV-infected patients and in 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-fed mice. Journal of Hepatology, 2013, 59, 738-745.	3.7	30
133	Dissecting the role of CB1 receptors on chronic liver diseases. Gut, 2013, 62, 957-958.	12.1	4
134	Invariant NKT cell activation induces neutrophil accumulation and hepatitis: Opposite regulation by IL-4 and IFN-Î³. Hepatology, 2013, 58, 1474-1485.	7.3	73
135	Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFÎ² receptor type II mice. Hepatology, 2013, 57, 806-816.	7.3	81
136	Progression of Chronic Liver Inflammation and Fibrosis Driven by Activation of c-JUN Signaling in Sirt6 Mutant Mice. Journal of Biological Chemistry, 2012, 287, 41903-41913.	3.4	142
137	Activation of Natural Killer T Cells Promotes M2 Macrophage Polarization in Adipose Tissue and Improves Systemic Glucose Tolerance via Interleukin-4 (IL-4)/STAT6 Protein Signaling Axis in Obesity. Journal of Biological Chemistry, 2012, 287, 13561-13571.	3.4	182
138	STAT proteins â€“ Key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. Journal of Hepatology, 2012, 57, 430-441.	3.7	146
139	Interleukin-22 Promotes Proliferation of Liver Stem/Progenitor Cells in Mice and Patients With Chronic Hepatitis B Virus Infection. Gastroenterology, 2012, 143, 188-198.e7.	1.3	138
140	Th17 Cells Regulate Liver Fibrosis by Targeting Multiple Cell Types: Many Birds With One Stone. Gastroenterology, 2012, 143, 536-539.	1.3	24
141	Interleukin-22 Ameliorates Cerulein-Induced Pancreatitis in Mice by Inhibiting the Autophagic Pathway. International Journal of Biological Sciences, 2012, 8, 249-257.	6.4	81
142	Cytokines and STATs in Liver Fibrosis. Frontiers in Physiology, 2012, 3, 69.	2.8	87
143	Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology, 2012, 56, 1150-1159.	7.3	348
144	Inflammation in Alcoholic Liver Disease. Annual Review of Nutrition, 2012, 32, 343-368.	10.1	229

#	Article	IF	Citations
145	Hepatoprotective and antiâ€inflammatory cytokines in alcoholic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 89-93.	2.8	162
146	Interferon-lambda (IFN-Î») induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. Journal of Leukocyte Biology, 2012, 93, 377-385.	3.3	92
147	Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology, 2011, 141, 1572-1585.	1.3	1,544
148	Enhanced Liver Regeneration in IL-10â€“Deficient Mice after Partial Hepatectomy via Stimulating Inflammatory Response and Activating Hepatocyte STAT3. American Journal of Pathology, 2011, 178, 1614-1621.	3.8	62
149	Hepatoprotective versus Oncogenic Functions of STAT3 in Liver Tumorigenesis. American Journal of Pathology, 2011, 179, 714-724.	3.8	58
150	AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice. Cell Metabolism, 2011, 13, 376-388.	16.2	1,356
151	NKT cells in liver fibrosis: Controversies or complexities. Journal of Hepatology, 2011, 55, 1166.	3.7	5
152	Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target. International Journal of Biological Sciences, 2011, 7, 536-550.	6.4	208
153	Molecular Mechanisms of Alcoholic Liver Disease: Innate Immunity and Cytokines. Alcoholism: Clinical and Experimental Research, 2011, 35, 787-793.	2.4	148
154	Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell and Bioscience, 2011, 1, 14.	4.8	63
155	Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology, 2011, 53, 73-85.	7.3	141
156	Suppression of innate immunity (natural killer cell/interferon-Î³) in the advanced stages of liver fibrosis in mice. Hepatology, 2011, 53, 1342-1351.	7.3	124
157	Natural killer cells take two tolls to destruct bile ducts. Hepatology, 2011, 53, 1076-1079.	7.3	16
158	In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology, 2011, 54, 252-261.	7.3	206
159	Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology, 2011, 54, 846-856.	7.3	145
160	Innate immunity in alcoholic liver disease. American Journal of Physiology - Renal Physiology, 2011, 300, G516-G525.	3.4	191
161	Structure and Mechanism of Receptor Sharing by the IL-10R2 Common Chain. Structure, 2010, 18, 638-648.	3.3	74
162	Natural killer group 2 member D, its ligands, and liver disease: Good or bad?. Hepatology, 2010, 51, 8-11.	7.3	24

#	Article	IF	Citations
163	Interplay of hepatic and myeloid signal transducer and activator of transcription 3 in facilitating liver regeneration via tempering innate immunity. Hepatology, 2010, 51, 1354-1362.	7.3	35
164	Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology, 2010, 51, 1724-1734.	7.3	60
165	Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. Hepatology, 2010, 52, 1291-1300.	7.3	364
166	Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice. Hepatology, 2010, 52, 2137-2147.	7.3	68
167	Antiâ€Inflammatory and Antiâ€Apoptotic Roles of Endothelial Cell STAT3 in Alcoholic Liver Injury. Alcoholism: Clinical and Experimental Research, 2010, 34, 719-725.	2.4	61
168	Th17 cells and their associated cytokines in liver diseases. Cellular and Molecular Immunology, 2010, 7, 250-254.	10.5	127
169	Toll-Like Receptor 3 in Liver Diseases. Gastroenterology Research and Practice, 2010, 2010, 1-6.	1.5	25
170	Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut, 2010, 59, 149-151.	12.1	11
171	Innate Immunity and Steatohepatitis: A Critical Role of Another Toll (TLR-9). Gastroenterology, 2010, 139, 27-30.	1.3	22
172	A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: Controlled by ATF3. Cellular Signalling, 2009, 21, 1758-1767.	3.6	58
173	Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology, 2009, 49, 1683-1694.	7.3	180
174	Molecular Mechanisms of Alcoholic Fatty Liver. Alcoholism: Clinical and Experimental Research, 2009, 33, 191-205.	2.4	269
175	Myeloid STAT3 Inhibits T Cell-Mediated Hepatitis by Regulating T Helper 1 Cytokine and Interleukin-17 Production. Gastroenterology, 2009, 137, 2125-2135.e2.	1.3	119
176	Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. Journal of Leukocyte Biology, 2009, 86, 513-528.	3.3	333
177	Liver: An organ with predominant innate immunity. Hepatology, 2008, 47, 729-736.	7.3	794
178	Natural killer T cells exacerbate liver injury in a transforming growth factor Î² receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology, 2008, 47, 571-580.	7.3	106
179	Innate immunity and alcoholic liver fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, S112-8.	2.8	53
180	Abrogation of the Antifibrotic Effects of Natural Killer Cells/Interferon-Î³ Contributes to Alcohol Acceleration of Liver Fibrosis. Gastroenterology, 2008, 134, 248-258.	1.3	223

#	Article	IF	Citations
181	Endocannabinoids, CB1 Receptors, and Liver Disease: Hitting More Than One Bird With the Same Stone. Gastroenterology, 2008, 134, 622-625.	1.3	8
182	Cell Typeâ€“Dependent Pro- and Anti-Inflammatory Role of Signal Transducer and Activator of Transcription 3 in Alcoholic Liver Injury. Gastroenterology, 2008, 134, 1148-1158.	1.3	179
183	Paracrine Activation of Hepatic CB1 Receptors byÂStellate Cell-Derived Endocannabinoids MediatesÂAlcoholic Fatty Liver. Cell Metabolism, 2008, 7, 227-235.	16.2	280
184	Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. American Journal of Physiology - Renal Physiology, 2008, 294, G850-G854.	3.4	42
185	Activation of innate immunity (NK/IFN-Î³) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation. American Journal of Physiology - Renal Physiology, 2008, 294, G1070-G1077.	3.4	31
186	Type I Natural Killer T (iNKT) Cells Regulate Inflammatory Immune Response in Mice Liver Injury Induced by CCl4. FASEB Journal, 2008, 22, 1072.16.	0.5	0
187	Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. American Journal of Physiology - Renal Physiology, 2007, 293, G809-G816.	3.4	113
188	Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Review of Gastroenterology and Hepatology, 2007, 1, 173-180.	3.0	54
189	Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology, 2007, 46, 504-513.	7.3	170
190	Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation. Alcohol, 2007, 41, 271-280.	1.7	46
191	Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery. Laboratory Investigation, 2007, 87, 1018-1028.	3.7	129
192	Role of the Proteasome in Ethanolâ€Induced Liver Pathology. Alcoholism: Clinical and Experimental Research, 2007, 31, 1446-1459.	2.4	46
193	Natural Killer Cells Ameliorate Liver Fibrosis by Killing Activated Stellate Cells in NKG2D-Dependent and Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Dependent Manners. Gastroenterology, 2006, 130, 435-452.	1.3	533
194	Poly I:C prevents T cell-mediated hepatitis via an NK-dependent mechanism. Journal of Hepatology, 2006, 44, 446-454.	3.7	81
195	Chronic Ethanol Consumption Inhibits Hepatic Natural Killer Cell Activity and Accelerates Murine Cytomegalovirus-Induced Hepatitis. Alcoholism: Clinical and Experimental Research, 2006, 30, 1615-1623.	2.4	58
196	Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism. Hepatology, 2006, 43, 1211-1219.	7.3	56
197	STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology, 2006, 44, 955-966.	7.3	62
198	STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology, 2006, 44, 1441-1451.	7.3	239

#	Article	IF	Citations
199	The complement system in liver diseases. Cellular and Molecular Immunology, 2006, 3, 333-40.	10.5	127
200	IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: Regulation by SOCS3. Biochemical and Biophysical Research Communications, 2005, 338, 1943-1949.	2.1	67
201	Cytokines, STATs and liver disease. Cellular and Molecular Immunology, 2005, 2, 92-100.	10.5	199
202	IL-6 Prevents T Cell-Mediated Hepatitis via Inhibition of NKT Cells in CD4+ T Cell- and STAT3-Dependent Manners. Journal of Immunology, 2004, 172, 5648-5655.	0.8	90
203	IFN-Î³/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. American Journal of Physiology - Renal Physiology, 2004, 287, G1044-G1052.	3.4	150
204	Chronic alcohol consumption accelerates liver injury in T cell-mediated hepatitis: alcohol disregulation of NF-ÎºB and STAT3 signaling pathways. American Journal of Physiology - Renal Physiology, 2004, 287, G471-G479.	3.4	51
205	Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology, 2004, 40, 933-941.	7.3	2
206	Host factors and failure of interferon-Î± treatment in hepatitis C virus. Hepatology, 2004, 39, 880-890.	7.3	142
207	Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology, 2004, 39, 1332-1342.	7.3	530
208	Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology, 2004, 40, 933-941.	7.3	185
209	Therapeutic potential of interleukin-6 in preventing obesity- and alcohol-associated fatty liver transplant failure. Alcohol, 2004, 34, 59-65.	1.7	53
210	Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-Î³). Gastroenterology, 2004, 127, 1525-1539.	1.3	178
211	Involvement of natural killer cells in PolyI:C-induced liver injury. Journal of Hepatology, 2004, 41, 966-973.	3.7	93
212	Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochemical Journal, 2004, 379, 199-208.	3.7	29
213	Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cellular and Molecular Immunology, 2004, 1, 43-9.	10.5	159
214	IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cellular and Molecular Immunology, 2004, 1, 205-11.	10.5	107
215	In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats1 1The authors thank Tim Lee (Moor Instruments Ltd., Millwey, United Kingdom) for assistance with Laser Doppler Image analysis.. Gastroenterology, 2003, 125, 202-215.	1.3	118
216	Crucial Role of IL-4/STAT6 in T Cell-Mediated Hepatitis: Up-Regulating Eotaxins and IL-5 and Recruiting Leukocytes. Journal of Immunology, 2003, 171, 3233-3244.	0.8	138

#	Article	IF	Citations
217	STAT1 plays an essential role in LPS/D-galactosamine-induced liver apoptosis and injury. American Journal of Physiology - Renal Physiology, 2003, 285, G761-G768.	3.4	56
218	Interferon-Î± activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology, 2002, 122, 1020-1034.	1.3	129
219	Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochemical and Biophysical Research Communications, 2002, 298, 297-302.	2.1	235
220	Interaction of alcohol and hepatitis viral proteins. Alcohol, 2002, 27, 69-72.	1.7	38
221	Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene, 2002, 21, 32-43.	5.9	154
222	Expression of interferon alfa signaling components in human alcoholic liver disease. Hepatology, 2002, 35, 425-432.	7.3	23
223	Opposing roles of STAT1 and STAT3 in T cellâ€“mediated hepatitis: regulation by SOCS. Journal of Clinical Investigation, 2002, 110, 1503-1513.	8.2	224
224	Opposing roles of STAT1 and STAT3 in T cellâ€“mediated hepatitis: regulation by SOCS. Journal of Clinical Investigation, 2002, 110, 1503-1513.	8.2	136
225	Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Letters, 2001, 488, 179-184.	2.8	104
226	Ethanol inhibits the JAK-STAT signaling pathway in freshly isolated rat hepatocytes but not in cultured hepatocytes or HepG2 cells: evidence for a lack of involvement of ethanol metabolism. Clinical Biochemistry, 2001, 34, 203-209.	1.9	29
227	Tumor necrosis factor Î± attenuates interferonâ€Î± signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB Journal, 2001, 15, 1595-1597.	0.5	70
228	Additive activation of hepatic NFâ€ºB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNFâ€Î± receptor 1â€independent and â€dependent mechanisms. FASEB Journal, 2001, 15, 2551-2553.	0.5	88
229	Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal) Tj ETQq1 1 0.784314 rgBT /Overl regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochemical Journal, 2000, 349, 427.	3.7	41
230	Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochemical Journal, 2000, 349, 427-434.	3.7	67
231	The concerted regulatory functions of the transcription factors nuclear factor-1 and upstream stimulatory factor on a composite element in the promoter of the hepatocyte growth factor gene. Oncogene, 2000, 19, 2786-2790.	5.9	14
232	IL-1Î² Attenuates IFN-Î±Î²-Induced Antiviral Activity and STAT1 Activation in the Liver: Involvement of Proteasome-Dependent Pathway. Journal of Immunology, 2000, 165, 3959-3965.	0.8	68
233	ILâ€10 attenuates IFNâ€Î±â€activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Letters, 2000, 480, 132-136.	2.8	90
234	Cross-talk between Î±1B-Adrenergic Receptor (Î±1BAR) and Interleukin-6 (IL-6) Signaling Pathways. Journal of Biological Chemistry, 1999, 274, 35492-35498.	3.4	29

#	Article	IF	Citations
235	Ethanol rapidly inhibits ILâ€6â€activated STAT3 and C/EBP mRNA expression in freshly isolated rat hepatocytes. FEBS Letters, 1999, 457, 162-168.	2.8	65
236	Histone H1 isoforms purified from rat liver bind nonspecifically to the nuclear factor 1 recognition sequence and serve as generalized transcriptional repressors. Molecular and Cellular Biochemistry, 1998, 178, 187-196.	3.1	11
237	Î±-Adrenergic inhibition of proliferation in HepG2 cells stably transfected with the Î±1B-adrenergic receptor through a p42MAPâ€ˆkinase/p21Cip1/WAF1-dependent pathway. FEBS Letters, 1998, 436, 131-138.	2.8	27
238	Effects of ethanol on mitogen-activated protein kinase and stress-activated protein kinase cascades in normal and regenerating liver. Biochemical Journal, 1998, 334, 669-676.	3.7	106
239	Effects of Short and Long Term Ethanol on the Activation of Signal Transducer and Activator Transcription Factor 3 in Normal and Regenerating Liver. Biochemical and Biophysical Research Communications, 1997, 239, 666-669.	2.1	38